Spruce Biosciences, Inc. (SPRB)

Spruce Biosciences's stock experienced significant events in the past six months. The stock surged after receiving FDA Breakthrough Therapy Designation for TA-ERT. They secured a loan facility from Avenue Capital Group, which may have caused investor concerns about potential shareholder dilution. The company reported its Third Quarter 2025 financial results and provided corporate updates. Oppenheimer initiated coverage with an "Outperform" recommendation, and Leerink Partners upgraded the stock. SPRB stock was delisted from Nasdaq for not meeting the minimum bid price requirement, but trading resumed later.

As a clinical-stage biopharmaceutical company, Spruce Biosciences does not have discernible demand seasonality for its products and services. The company's revenue streams are primarily from collaboration agreements and capital raising to fund its R&D programs, rather than product sales.

Spruce Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for rare endocrine and neurological disorders. Their major product candidates include Tildacerfont, an oral CRF1 receptor antagonist for CAH and polycystic ovary syndrome, and Tralesinidase Alfa (TA-ERT), an enzyme replacement therapy for Sanfilippo Syndrome Type B (MPS IIIB).

Spruce Biosciences is headquartered in South San Francisco, California. They have a collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. for Tildacerfont in Japan, indicating international reach.

Spruce Biosciences has a brand reputation tied to its clinical development progress and regulatory milestones. The company has a "Moderate Buy" consensus rating from analysts. MarketBeat's MarketRank™ scored Spruce Biosciences higher than 72% of evaluated companies. The FDA Breakthrough Therapy Designation boosted confidence, while the Nasdaq delisting negatively impacted its reputation.

Spruce Biosciences, Inc. has significant institutional ownership, with 17 institutional owners and shareholders holding a total of 2,937,895 shares. Major institutional owners include Carlyle Group Inc., Cable Car Capital LLC, Ikarian Capital, LLC, Lion Point Capital, LP, Advisor Group Holdings, Inc., UBS Group AG, Morgan Stanley, Caldwell Securities, Inc and Bank Of America Corp /de/. Individual investors like Kenneth Griffin also hold shares.